biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (3623)	11/19/2018 8:28:25 PM
From: Biotech Jim	Read Replies (1) of 3661

I have not been following IFRX as closely as I used to, as they seemed overvalued considering their stage of clinical development. The stock price was so solid, I got tired of waiting for it to fall back. IFRX will likely have to perform a Ph 3 in HS. I talked to a local dermatology resident and her mentor several months back regarding HS patients they saw. They actually were quite familiar with the condition and have seen patients, and believe it is a significant unmet medical despite the fact that Humira has (limited) activity in HS. They were unaware of the IFRX work in the clinic, not all that unusual considering their patient load.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next